{"id":665461,"date":"2023-08-29T09:06:01","date_gmt":"2023-08-29T09:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=665461"},"modified":"2023-08-29T09:06:01","modified_gmt":"2023-08-29T09:06:01","slug":"high-schoolerrun-startup-vytal-secures-12-million-in-seed-funding-at-a-valuation-of-125-million","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/high-schoolerrun-startup-vytal-secures-12-million-in-seed-funding-at-a-valuation-of-125-million_665461.html","title":{"rendered":"High Schooler-Run Startup Vytal Secures $1.2 Million in Seed Funding at a Valuation of $12.5 Million"},"content":{"rendered":"
\n
\"High<\/a><\/div>\n
\n
Vytal is positioning itself to make a significant contribution to the field of Neurology. <\/div>\n<\/div>\n<\/div>\n
The company is on a mission to transform the landscape of healthcare<\/div>\n

Alexandria, Va. – August 29th, 2023 –<\/strong> Vytal<\/a>, a pioneering startup founded by high schoolers Sai Mattapalli<\/a> and Rohan Kalahasty<\/a>, has successfully raised $1.2 million in seed funding with a valuation of $12.5 million. <\/p>\n

Prominent investors led the funding, including Powerhouse Ventures, LSCP Investments, and Diamond Investments. This milestone represents a remarkable achievement for a startup led by young entrepreneurs in healthcare technology.<\/p>\n

Vytal aims to transform healthcare through its innovative web and mobile deep learning application. Navigating the challenges of startup funding in 2023, Vytal’s strategic approach focused on a global perspective. <\/p>\n

“Startup funding in 2023 is possibly the lowest it’s been in the last few decades,” Mattapalli explained. “We overcame this with Vytal by focusing on investors across the ocean. Specifically, India is witnessing a surge of hype surrounding startup culture and funding, which we were able to capitalize on by having close connections and giving talks about Vytal at the 2023 India Startup Fest.”<\/p>\n

Vytal’s success story exemplifies the power of innovation, dedication, and collaboration. With a commitment to inclusivity and accessibility, the startup is positioning itself to make a significant contribution to the field of neurology. By providing objective diagnostics and early intervention tools, Vytal aims to empower individuals, healthcare professionals, and researchers to create a healthier and more equitable future.<\/p>\n

Rohan mentions that “Vytal’s success thus far has been primarily because of the almost perfect co-founder fit” between Sai and him.” “Innovation in the healthcare space can be challenging, but our current team shares the same drive and determination as us, and we look forward to a very exciting future,” concludes Rohan.  <\/p>\n

“The ever-growing SaaMD (software as a medical device) space is the perfect environment for aspiring entrepreneurs to hone in on as growth and advancement in the medical field is necessary,” said Mattapalli.<\/p>\n

With the official launch of the waitlist for Beta Testing, Vytal.ai is poised to make significant strides in the health tech sector. To learn more about Vytal.ai and its cutting-edge technology, please visit vytal.ai<\/a>.<\/p>\n

Rohan Kalahasty<\/strong><\/p>\n

Kalahasty is the Co-Founder and CEO of Vytal.ai<\/a>. He has been a researcher at the Harvard Ophthalmology AI Lab for three years, where he led and incubated NeurOS and worked on projects leveraging mathematical, statistical, and artificial intelligence modeling to enhance eye disease diagnosis. Furthermore, he served as an incubation lead at Roivant Sciences, leading the early stages of a potential new vant. He has also researched at the Center for Brains, Minds, and Machines at MIT, where he dedicated his time to studying human intelligence and memory utilizing artificial intelligence. While working with these groups, he has developed a deep insight into the intersection of AI and Medicine and the creation of digital biomarkers, an insight which has proved crucial for the development of Vytal.He has a focus on interdisciplinary endeavors that have the potential to make an impact in the world. He is a senior at Thomas Jefferson High School for Science and Technology.<\/p>\n

Sai Mattapali<\/strong><\/p>\n

Initially focused on behavioral neuroscience, Sai was a research intern at the Neurophysiology Lab at Georgetown University, where he built behavioral paradigms to test auditory learning in Zebrafish. Later pivoting to entrepreneurship and finance, Sai served as a business growth intern at Quantbase (YC W23) and was a part of DMV’s Finest, the winners of the Wharton Investment Competition. The amalgamation of his experiences led him to where he is today, leading Vytal with Rohan, with aspirations to be an entrepreneur in the medical space.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Vytal<\/a>
Contact Person:<\/strong> Dave Purdy
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 7274002578
Address:<\/strong>136 4th St N Ste 201
City:<\/strong> St. Petersburg
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> www.otterpr.com<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Vytal is positioning itself to make a significant contribution to the field of Neurology. The company is on a mission to transform the landscape of healthcare Alexandria, Va. – August 29th, 2023 – Vytal, a pioneering startup founded by high … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,406,420,411,404],"tags":[],"class_list":["post-665461","post","type-post","status-publish","format-standard","hentry","category-Business","category-Pharmaceuticals-Biotech","category-Science","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/665461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=665461"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/665461\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=665461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=665461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=665461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}